Authors
Latest:
Oncology Fellows Derive the Greatest Benefit From Advanced Research TrainingAimed at growing the translational workforce, most hubs offer different accelerated advanced degree opportunities to oncology trainees, such as master’s degrees in clinical and/or translational research, or graduate certificates.
Latest:
A Gut Check on the Digital Divide: How Wearable Devices Are Changing Cancer CareThe idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.
Latest:
Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast CancerJulie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.
Latest:
Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLCMisako Nagasaka, MD, discusses key data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ non–small cell lung cancer.
Latest:
Darolutamide Plus Docetaxel/ADT Does Not Increase Hospitalization in mHSPCDarolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Mohyuddin on Improving Survival in Multiple MyelomaGhulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.
Latest:
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell LymphomaJason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Latest:
Dr. del Rio on Remaining Questions With the COVID-19 VaccinesCarlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.
Latest:
Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell TherapyAlba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.
Latest:
KRAS G12C Inhibitors in mCRCA brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.
Latest:
Dr. Nguyen on Enrollment Disparities in Pivotal Clinical Trials in OncologyRyan Nguyen, DO, discusses enrollment disparities in pivotal clinical trials in oncology.
Latest:
Dr. Majhail on the Importance of Utilizing Social Media in OncologyNavneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.
Latest:
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast CancerHeather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.
Latest:
Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer CellsSheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.
Latest:
Novel HER2-Targeted Therapies for NSCLCClosing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Latest:
Getting the Best From MentorshipMentors may help in career development, personal matters, research activities, and professional growth.
Latest:
Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR MutationsAaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.
Latest:
Dr Vaz Batista on Treating Patients With HER2+ Breast Cancer and Leptomeningeal CarcinomatosisMarta Vaz Batista, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis, as evaluated in cohort 5 of the phase 2 DEBBRAH study.
Latest:
Frontline Therapeutic Planning for Metastatic Renal Cell CarcinomaIn this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.
Latest:
Dr. Park on the Role of Cemiplimab in Advanced Basal Cell CarcinomaSoo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.
Latest:
Dr. Giaconne on the Lack of Funding for Rare Cancers ResearchGiuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.
Latest:
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC TreatmentCoral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in CancerRanjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.
Latest:
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment LandscapeClosing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Latest:
Dr. Ross on the Role of the Microbiome in CRCHoward M. Ross, MD, discusses the role of the microbiome colorectal cancer.
Latest:
In the Trenches With the FellowsMili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.
Latest:
SCLC: Future Therapies and Advice to Community OncologistsDrs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.
Latest:
Novel Treatment Combinations in Chronic Lymphocytic LeukemiaDr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.
